Advancing Treatment in Gastroenterology™

Salix's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

Salix Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

RALEIGH, NC, January 8, 2014 Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at The 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2014 at 4:30 p.m. PT (7:30 p.m. ET).

Interested parties can access a live audio web cast of the presentation at http://www.salix.com. A replay of the presentation will be available at the same location.

About Salix

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and market them through Salix's gastroenterology specialty sales and marketing team.

Salix trades on the NASDAQ Global Select Market under the ticker symbol "SLXP".

For more information, please visit our website at www.salix.com or contact Salix at 919-862-1000. Follow us on Twitter (@SalixPharma) and Facebook (www.facebook.com/SalixPharma). Information on our Twitter feed, Facebook page and web site is not incorporated in our filings with the U.S. Securities and Exchange Commission (the "SEC").

 

Recent tweets

Sign up for the Digestive Health Newsletter

Email address

Yes, I would also like to receive additional product and healthcare information from Salix Pharmaceuticals.

Rss Feed Logo

Thank you for signing up. You will receive a confirmation email shortly./p>

newsletter-bottom.png


Home About Us Products Healthcare Professional Resources Patient Resources Investors News & Media Careers Contact Us Site Map

Mobile Site

A message from
Carolyn Logan, CEO of Salix Pharmaceuticals

At Salix, we work hard every day to meet the current and anticipated needs of patients and healthcare providers. We are excited about the opportunity to drive this mission forward and are pleased to announce the successful completion of the acquisition of Santarus, Inc. We are looking forward to creating a new company with greater scope and impact than either company could offer independently. This is a transformational event for Salix and an important milestone in our growth as the leading company in gastrointestinal disease.

Close

Use of this site signifies your agreement to the Terms of Use. Privacy Policy.

©2014 Salix Pharmaceuticals, Inc. All rights reserved. SWB 10/06-36

8510 Colonnade Center Drive, Raleigh, NC 27615 USA T: 919-862-1000, F: 919-862-1095

News Source : Advancing Treatment in Gastroenterology™

Copy this html code to your website/blog to embed this press release.